Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs
A Phase Ib, Open-Label Trial of MOv18 IgE in Patients with Advanced Ovarian Cancer
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Axel Walther (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A Phase Ib Open-Label Trial of MOv18 IgE in Patients with Advanced Ovarian Cancer
MOV18-02 - EPS101-10-02: A Phase 1b Open-Label Trial of MOv18 IgE in Patients with Advanced Ovarian Cancer
Preclinical development & CRUKD/14/001 A Cancer Research UK Phase I trial of MOv18, a first in class chimaeric IgE antibody against folate receptor-alpha, in patients with advanced solid tumours including ovarian, colorectal & mesothelioma
Preclinical efficacy and safety evaluation of MOv18 IgE, a novel class of antibody targeting alpha folate receptor
A Cancer Research UK Phase I study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-alpha, in patients with advanced solid tumours
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know